Some mixed Hodge structure on l^2-cohomology of covering of K\"ahler manifolds

We give methods to compute l^2-cohomology groups of a covering manifolds obtained by removing pullback of a (normal crossing) divisor to a covering of a compact K\"ahler manifold. We prove that in suitable quotient categories, these groups admit natural mixed Hodge structure whose graded pieces are given by expected Gysin maps.Comment: 40 pages. This revised version will be published in Mathematische Annale

Heat transfer phase change paint test (OH-42) of a Rockwell International SSV orbiter in the NASA/LRC Mach 8 variable density wind tunnel

Phase change paint tests of a Rockwell International .00593-scale space shuttle orbiter were conducted in the Langley Research Center's Variable Density Wind Tunnel. The test objectives were to determine the effects of various wing/underbody configurations on the aerodynamic heating rates and boundary layer transition during simulated entry conditions. Several models were constructed. Each varied from the other in either wing cuff radius, airfoil thickness, or wing-fuselage underbody blending. Two ventral fins were glued to the fuselage underside of one model to test the interference heating effects. Simulated Mach 8 entry data were obtained for each configuration at angles of attack ranging from 25 to 40 deg, and a Reynolds number variation of one million to eight million. Elevon, bodyflap, and rudder flare deflections were tested. Oil flow visualization and Schlieren photographs were obtained to aid in reducing the phase change paint data as well as to observe the flow patterns peculiar to each configuration

1985: Abilene Christian College Bible Lectures - Full Text

WHAT THE CHURCH NEEDS TO HEAR Being the Abilene Christian University Annual Bible Lectures 1985 Published by A-C-U PRESS ACU Station Abilene, Texas 7969

The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

BACKGROUND: The existing estimate of the global burden of latent TB infection (LTBI) as "one-third" of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI. METHODS AND FINDINGS: We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%-26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%-0.9%) of the global population, amounting to 55.5 (95% UI: 48.2-63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI. CONCLUSIONS: We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached